The goal of the UCLA SPORE in Brain Cancer Developmental Research Program (DRP) is to foster the exploration of innovative research ideas through the funding of pilot developmental research projects in the field of brain cancer. This program will identify new, innovative projects for funding that will constantly renew the vigor of our Brain SPORE research portfolio and add to, augment, or replace current major research projects. The DRP represents a timely mechanism to expand discovery within the SPORE. Each year, three highly innovative proposals will be selected for funding. Prospective developmental research projects will be solicited through a request for applications (RFA) sent throughout the UCLA main campus and affiliated institutions (i.e., LA BioMed/UCLA Harbor Medical Center, Charles Drew University of Medicine and Science, West Los Angeles Veterans Administration Hospital, Southern California Kaiser Permanente, and Cedars-Sinai Medical Center). We will also solicit proposals for our DRP through other institution-wide, state-wide, and region-wide channels. This will include e-mail solicitations to all faculty at UCLA and other University of California campuses (Berkeley, Davis, Irvine, Riverside, San Diego, Santa Barbara, and Santa Cruz), as well as to researchers at Caltech and USC. We will also solicit applications through the major NCI-funded Cancer Centers in Southern California (UCLA Jonsson Cancer Center, USC Norris Cancer Center, City of Hope Cancer Center, UCI Chao Family Cancer Center, UCSD Moores Cancer Center, Sanford-Burnham Research Institute, and the Salk Institute). Potential DRP investigators will be asked for a proposal, biosketch, and letters of recommendation. Three awards of $50,000 each (totaling $150,000 per year) will be made annually for the duration of the SPORE award. Funding will be made primarily for new and innovative ideas, but also to initiate intra- and inter-SPORE collaborations. Faculty at all levels will be encouraged to apply, both those beginning a research career, and established investigators who wish to re-direct their research into the field of brain cancer. This should provide a broad base of applicants and new ideas, providing funding opportunities for investigators from a variety of local and regional institutions. The DRP Selection Committee will meet and select the most meritorious translational brain cancer research applications, with input from outside ad hoc reviewers as necessary. Following scoring by the DRP Selection Committee, the Executive Committee (EC) will meet to determine the funding line. The Internal Advisory Board (IAB) and External Advisory Board (EAB) will review the funding decisions and progress of developmental projects at their regularly scheduled meetings. The DRP will receive matching funds from the Jonsson Comprehensive Cancer Center (JCCC) and the UCLA Department of Neurosurgery. Successful translational research projects may receive further funding in the SPORE and replace unproductive funded major projects. The anticipated outcome of the DRP is to enlarge the overall pool of brain cancer SPORE investigators at UCLA.

Public Health Relevance

DRP: Developmental Research Program NARRATIVE A central mission of the UCLA SPORE in Brain Cancer, if funded, is to allocate a significant effort to support innovative pilot projects that can take maximal advantage of new research opportunities, cores, and collaborations that may result from receiving a new SPORE award. High risk/high reward developmental projects will be especially encouraged through the Developmental Research Program (DRP). Addressing the overall problem of brain cancer will require us to develop such new avenues of research with novel translational investigations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA211015-04
Application #
9983051
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2017-08-11
Project End
2022-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
4
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Laks, Dan R; Oses-Prieto, Juan A; Alvarado, Alvaro G et al. (2018) A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma. Neuro Oncol 20:764-775
Kirsch, David G; Diehn, Max; Kesarwala, Aparna H et al. (2018) The Future of Radiobiology. J Natl Cancer Inst 110:329-340
Omuro, Antonio; Vlahovic, Gordana; Lim, Michael et al. (2018) Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol 20:674-686
Magaki, Shino; Tang, Zhaoyi; Tung, Spencer et al. (2018) The effects of cerebral amyloid angiopathy on integrity of the blood-brain barrier. Neurobiol Aging 70:70-77
Woodworth, Davis C; Holly, Langston T; Mayer, Emeran A et al. (2018) Alterations in Cortical Thickness and Subcortical Volume are Associated With Neurological Symptoms and Neck Pain in Patients With Cervical Spondylosis. Neurosurgery :
Magaki, Shino D; Williams, Christopher K; Vinters, Harry V (2018) Glial function (and dysfunction) in the normal & ischemic brain. Neuropharmacology 134:218-225
Tubi, Meral A; Lutkenhoff, Evan; Blanco, Manuel Buitrago et al. (2018) Early seizures and temporal lobe trauma predict post-traumatic epilepsy: A longitudinal study. Neurobiol Dis :
Camacho, Jessica; Truong, Lisa; Kurt, Zeyneb et al. (2018) The Memory of Environmental Chemical Exposure in C. elegans Is Dependent on the Jumonji Demethylases jmjd-2 and jmjd-3/utx-1. Cell Rep 23:2392-2404
Liau, Linda M; Ashkan, Keyoumars; Tran, David D et al. (2018) Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 16:179
Nowosielski, Martha; Ellingson, Benjamin M; Chinot, Olivier L et al. (2018) Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. Neuro Oncol 20:557-566

Showing the most recent 10 out of 91 publications